Patients in England and Wales with chronic lymphocytic leukaemia (CLL) could soon benefit from Gazyvaro, after the National Institute for Health and Care Excellence (NICE) issued a positive Final Appraisal Determination (FAD) today recommending the drug for routine use on the NHS.
Gazyvaro has been recommended for use in combination with chlorambucil chemotherapy for the treatment of previously-untreated adult patients with CLL who have co-existing medical conditions that make them unsuitable for other aggressive treatments.
Professor Chris Bunce, Research Director at Leukaemia & Lymphoma Research, said: “NICE’s decision will come as a relief to numerous patients with chronic lymphocytic leukaemia who lack effective treatment options. Many are elderly at diagnosis and can have underlying medical conditions that prevent them from undergoing gruelling toxic treatments. Gazyvaro, in combination with mild chemotherapy, can significantly prolong survival times for these patients.”
This latest announcement backs up an earlier appraisal issued by NICE in December 2014. Final guidance confirming Gazyvaro’s use on the NHS is expected later in the year.